Patent ID: 8592391

Claim:
A method for treatment in humans of gliomas, melanoma, breast and lung cancer, colon cancer, sarcomas, renal cell cancer, leukemias, lymphomas, viral infections caused by influenza virus, flavivirus, West Nile virus, Japanese encephalitis virus, dengue virus, yellow fever virus, SARS coronavirus, ebola virus, adenovirus, hepatitis virus, herpesviruses, and human immunodeficiency virus; the autoimmune conditions multiple sclerosis, Guillain Barre syndrome, immune neuropathy, and vasculitis, and ionizing radiation injury; comprising: preparing a Poly-ICLC complex of high molecular weight polyriboinosinic-polyribocytidylic acid double stranded RNA (Poly-IC), low molecular weight poly-l-lysine, and carboxymethylcellulose, by adding poly-L-lysine solution slowly to a carboxymethylcellulose solution over a period of at least 4 days and mixing for the entire blending time vigorously enough to form a vortex and minimize precipitate buildup, followed by addition of the poly-IC component solution; and administering the Poly-ICLC solution intranasally, orally, sublingually, intramuscularly, intravenously, transdermally or topically in at least two doses spaced 4-72 hours apart, where dose is in a range of 10-40 mg/kg body weight in humans sufficient for unblocking and stimulation of interferon and of the dsRNA dependent host defense systems PKR 2′5′OAS, RIG-I Helicase, and Toll-like receptor 3.